Equities

Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)84.99
  • Today's Change-0.70 / -0.82%
  • Shares traded464.51k
  • 1 Year change+43.03%
  • Beta0.9590
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform11
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 16 analysts offering 12 month price targets for Intra-Cellular Therapies Inc have a median target of 100.00, with a high estimate of 135.00 and a low estimate of 76.58. The median estimate represents a 16.70% increase from the last price of 85.69.
High57.5%135.00
Med16.7%100.00
Low-10.6%76.58

Earnings history & estimates in USD

On Oct 30, 2024, Intra-Cellular Therapies Inc reported 3rd quarter 2024 losses of -0.25 per share.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate-7.40%
Intra-Cellular Therapies Inc reported annual 2023 losses of -1.46 per share on Feb 22, 2024.
Average growth rate+9.93%
More ▼

Revenue history & estimates in USD

Intra-Cellular Therapies, Inc. had 3rd quarter 2024 revenues of 175.38m. This bettered the 172.35m consensus of the 14 analysts covering the company. This was 84.01% above the prior year's 3rd quarter results.
Average growth rate+8.61%
Intra-Cellular Therapies, Inc. had revenues for the full year 2023 of 464.37m. This was 85.51% above the prior year's results.
Average growth rate+9,618.31%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.